Literature DB >> 3284386

Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role.

S Vilaró1, M Llobera, G Bengtsson-Olivecrona, T Olivecrona.   

Abstract

We have studied the binding and metabolism of 125I-labeled bovine lipoprotein lipase (LPL) by use of isolated, perfused rat livers. Our data suggest the presence of two types of binding sites, i.e., heparin-sensitive sites that bind primarily the catalytically active form of the lipase and are present at the endothelium in all blood vessels and heparin-insensitive sites that bind both active and inactive forms and are present only within the sinusoids. Forty minutes after uptake by the liver, approximately 50% of the LPL had lost its catalytic activity or been degraded. Three processes were evident: 1) colchicine-sensitive degradation to acid-soluble products, 2) partial proteolysis to fragments similar to those formed by limited digestion with trypsin or plasmin, and 3) a conformational change leading to loss of catalytic activity. Exogenous LPL bound in the liver caused a dramatic increase in the utilization of a perfused triacylglycerol emulsion (Intralipid), with rapid formation of free fatty acids and water-soluble metabolites. When the liver was flushed with heparin, it lost its ability to utilize the fat emulsion. Measurement of the hepatic extraction showed that rat livers take up 100-200 mU endogenous LPL per hour.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284386     DOI: 10.1152/ajpgi.1988.254.5.G711

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Secretion of hepatic lipase by perfused liver and isolated hepatocytes.

Authors:  X Galan; M Q Robert; M Llobera; I Ramírez
Journal:  Lipids       Date:  2000-09       Impact factor: 1.880

2.  Lipoprotein lipase activity in neonatal-rat liver cell types.

Authors:  F Burgaya; J Peinado; S Vilaró; M Llobera; I Ramírez
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

3.  Effect of protamine on lipoprotein lipase and hepatic lipase in rats.

Authors:  M Hultin; G Olivecrona; T Olivecrona
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

4.  Heparin-decasaccharides impair the catabolism of chylomicrons.

Authors:  O Chevreuil; M Hultin; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

5.  Structure of heparin fragments with high affinity for lipoprotein lipase and inhibition of lipoprotein lipase binding to alpha 2-macroglobulin-receptor/low-density-lipoprotein-receptor-related protein by heparin fragments.

Authors:  A Larnkjaer; A Nykjaer; G Olivecrona; H Thøgersen; P B Ostergaard
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

6.  Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein.

Authors:  U Beisiegel; W Weber; G Bengtsson-Olivecrona
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

7.  Rat liver contains a limited number of binding sites for hepatic lipase.

Authors:  K Schoonderwoerd; A J Verhoeven; H Jansen
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

8.  Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis.

Authors:  Eva Pardina; Juan A Baena-Fustegueras; Rafael Llamas; Roberto Catalán; Rosa Galard; Albert Lecube; Jose M Fort; Miquel Llobera; Helena Allende; Víctor Vargas; Julia Peinado-Onsurbe
Journal:  Obes Surg       Date:  2009-03-20       Impact factor: 4.129

9.  Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

Authors:  G Q Liu; G Bengtsson-Olivecrona; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

10.  Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis.

Authors:  Dana Mahmood; Maria Grubbström; Lennart D I Lundberg; Gunilla Olivecrona; Thomas Olivecrona; Bernd G Stegmayr
Journal:  BMC Nephrol       Date:  2010-12-06       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.